/
PRQR
$1.83+$0.30 (+19.61%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$161.2M
105M shares
52-week range
$1.33 – $3.10
28% from low
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-4.91
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9M | $1.9M | $1.0M | $1.3M | $3.6M | $6.5M | $18.9M | $15.3M |
| Cost of revenue | $983.5K | $116.8M | $0 | $0 | $0 | $0 | $0 | $2.6M |
| Gross profit | $4.0M | −$114.9M | $1.0M | $1.3M | $3.6M | $6.5M | $18.9M | $12.7M |
| Gross margin | 80.1% | -5943.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 83.0% |
| R&D | $29.5M | $46.5M | $38.1M | $42.2M | $50.9M | $25.1M | $36.4M | $40.7M |
| Operating income | −$36.3M | −$57.4M | −$42.4M | −$57.2M | −$65.2M | −$31.9M | −$30.5M | −$42.2M |
| EBITDA | −$35.3M | −$174.3M | −$48.4M | −$54.9M | −$56.5M | −$24.1M | −$24.1M | −$37.0M |
| Net income | −$36.9M | −$56.7M | −$46.6M | −$60.7M | −$64.4M | −$28.1M | −$27.8M | −$40.5M |
| Net margin | -746.7% | -2935.6% | -4525.3% | -4549.8% | -1792.5% | -431.7% | -146.9% | -265.2% |
| EPS (diluted) | -1.08 | -1.38 | -0.93 | -0.96 | -0.91 | -0.35 | -0.34 | -0.38 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-0.48 | $-0.55–$-0.37 | 4 |
| 2027 | $18M | $-0.55 | $-0.85–$-0.34 | 4 |
| 2028 | $43M | $-0.35 | $-0.66–$0.08 | 4 |
| 2029 | $67M | $-0.40 | $-0.54–$-0.18 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
ProQR Therapeutics N.V. Ordinary Shares
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
www.proqr.com- Employees
- 187
- IPO / List date
- Sep 18, 2014
Held by traders on TradeandTell
No one on the platform currently holds PRQR.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PRQR as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PRQR yet.
